Which has better valuation & earnings, ORPH or IXI?

Open Orphan has higher revenue and earnings than IXICO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Open Orphan £34.71M 0.00 N/A N/A N/A IXICO £7.28M 2.28 -£3.58M -£1.95 N/A

Is ORPH or IXI more profitable?

Open Orphan has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Open Orphan's return on equity of 0.00% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets Open Orphan N/A N/A N/A IXICO -24.98% -16.18% -10.40%

Which has higher valuation & earnings, REDX or IXI?

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redx Pharma £4.20M 0.00 -£33.16M -£0.10 N/A IXICO £7.28M 2.28 -£3.58M -£1.95 N/A

Is REDX or IXI more profitable?

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Redx Pharma N/A -180.80% -43.95% IXICO -24.98% -16.18% -10.40%

Which has stronger valuation & earnings, ETX or IXI?

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio e-therapeutics £295K 0.00 -£10.06M -£0.02 N/A IXICO £7.28M 2.28 -£3.58M -£1.95 N/A

Is ETX or IXI more profitable?

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets e-therapeutics N/A -38.75% -29.10% IXICO -24.98% -16.18% -10.40%

Do analysts recommend HVO or IXI?

hVIVO currently has a consensus target price of GBX 15, suggesting a potential upside of 114.29%. Given hVIVO's stronger consensus rating and higher probable upside, research analysts clearly believe hVIVO is more favorable than IXICO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 IXICO 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, HVO or IXI?

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 1.03 £17.84M -£0.87 N/A IXICO £7.28M 2.28 -£3.58M -£1.95 N/A

Is HVO or IXI more profitable?

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% IXICO -24.98% -16.18% -10.40%

IXICO (IXI) Competitors

GBX 7.57 -0.43 (-5.39%)

As of 11:15 AM Eastern

Compare

IXI vs. ORPH, REDX, ETX, HVO, and HEMO

Should you buy IXICO stock or one of its competitors? MarketBeat compares IXICO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IXICO include Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), hVIVO (HVO), and Hemogenyx Pharmaceuticals (HEMO). These companies are all part of the "biotechnology" industry.

How does IXICO compare to Open Orphan?

Open Orphan (LON:ORPH) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Open Orphan has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Open Orphan's return on equity of 0.00% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Open Orphan	N/A	N/A	N/A
IXICO	-24.98%	-16.18%	-10.40%

In the previous week, Open Orphan's average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.

Company	Overall Sentiment
Open Orphan	Neutral
IXICO	Neutral

13.0% of IXICO shares are held by institutional investors. 3.0% of IXICO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Open Orphan has higher revenue and earnings than IXICO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Open Orphan	£34.71M	0.00	N/A	N/A	N/A
IXICO	£7.28M	2.28	-£3.58M	-£1.95	N/A

Summary

Open Orphan beats IXICO on 4 of the 7 factors compared between the two stocks.

How does IXICO compare to Redx Pharma?

Redx Pharma (LON:REDX) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, IXICO has a beta of 0.129, indicating that its share price is 87% less volatile than the broader market.

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A
IXICO	£7.28M	2.28	-£3.58M	-£1.95	N/A

In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.

Company	Overall Sentiment
Redx Pharma	Neutral
IXICO	Neutral

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redx Pharma	N/A	-180.80%	-43.95%
IXICO	-24.98%	-16.18%	-10.40%

72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 18.4% of Redx Pharma shares are held by insiders. Comparatively, 3.0% of IXICO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IXICO beats Redx Pharma on 6 of the 10 factors compared between the two stocks.

How does IXICO compare to e-therapeutics?

e-therapeutics (LON:ETX) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

26.5% of e-therapeutics shares are owned by institutional investors. Comparatively, 13.0% of IXICO shares are owned by institutional investors. 59.4% of e-therapeutics shares are owned by company insiders. Comparatively, 3.0% of IXICO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

e-therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, IXICO has a beta of 0.129, indicating that its share price is 87% less volatile than the broader market.

In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.

Company	Overall Sentiment
e-therapeutics	Neutral
IXICO	Neutral

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A
IXICO	£7.28M	2.28	-£3.58M	-£1.95	N/A

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
e-therapeutics	N/A	-38.75%	-29.10%
IXICO	-24.98%	-16.18%	-10.40%

Summary

e-therapeutics and IXICO tied by winning 5 of the 10 factors compared between the two stocks.

How does IXICO compare to hVIVO?

hVIVO (LON:HVO) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

hVIVO currently has a consensus target price of GBX 15, suggesting a potential upside of 114.29%. Given hVIVO's stronger consensus rating and higher probable upside, research analysts clearly believe hVIVO is more favorable than IXICO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.03	£17.84M	-£0.87	N/A
IXICO	£7.28M	2.28	-£3.58M	-£1.95	N/A

In the previous week, hVIVO's average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
IXICO	Neutral

11.8% of hVIVO shares are owned by institutional investors. Comparatively, 13.0% of IXICO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 3.0% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

hVIVO has a beta of 1.707, meaning that its stock price is 71% more volatile than the broader market. Comparatively, IXICO has a beta of 0.129, meaning that its stock price is 87% less volatile than the broader market.

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
IXICO	-24.98%	-16.18%	-10.40%

Summary

hVIVO beats IXICO on 11 of the 14 factors compared between the two stocks.

How does IXICO compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%
IXICO	-24.98%	-16.18%	-10.40%

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
IXICO	Neutral

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of IXICO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hemogenyx Pharmaceuticals has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, IXICO has a beta of 0.129, suggesting that its share price is 87% less volatile than the broader market.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than IXICO. IXICO is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A
IXICO	£7.28M	2.28	-£3.58M	-£1.95	N/A

Summary

Hemogenyx Pharmaceuticals and IXICO tied by winning 5 of the 10 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXI vs. The Competition

Export

Metric	IXICO	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£16.57M	£3.58B	£6.87B	£2.86B
Dividend Yield	1.27%	3.76%	2.60%	6.13%
P/E Ratio	-3.88	7.68	280.34	368.57
Price / Sales	2.28	1,307.29	600.23	83,546.92
Price / Cash	2.25	103.01	71.79	27.89
Price / Book	0.39	17.16	12.97	7.14
Net Income	-£3.58M	-£12.52M	£3.49B	£5.89B
7 Day Performance	-5.68%	4.15%	3.57%	1.00%
1 Month Performance	-10.95%	-5.02%	-2.50%	0.67%
1 Year Performance	-41.55%	50.34%	73.94%	74.90%

IXICO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXI IXICO	N/A	GBX 7.57 -5.4%	N/A	-41.8%	£16.57M	£7.28M	N/A	89	Gap Down
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume
HVO hVIVO	N/A	GBX 7.06 -2.0%	GBX 15 +112.6%	-26.9%	£48.57M	£46.77M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IXICO (IXI) Competitors